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Background: Recent successes in the determination of G-protein coupled receptor (GPCR) structures have relied on
the ability of receptor variants to overcome difficulties in expression and purification. Therefore, the quick screening
of functionally expressed stable receptor variants is vital.
Results: We developed a platform using Saccharomyces cerevisiae for the rapid construction and evaluation of
functional GPCR variants for structural studies. This platform enables us to perform a screening cycle from construction
to evaluation of variants within 6–7 days. We firstly confirmed the functional expression of 25 full-length class A GPCRs
in this platform. Then, in order to improve the expression level and stability, we generated and evaluated the variants
of the four GPCRs (hADRB2, hCHRM2, hHRH1 and hNTSR1). These stabilized receptor variants improved both functional
activity and monodispersity. Finally, the expression level of the stabilized hHRH1 in Pichia pastoris was improved up to
65 pmol/mg from negligible expression of the functional full-length receptor in S. cerevisiae at first screening. The
stabilized hHRH1 was able to be purified for use in crystallization trials.
Conclusions: We demonstrated that the S. cerevisiae system should serve as an easy-to-handle and rapid platform for
the construction and evaluation of GPCR variants. This platform can be a powerful prescreening method to identify a
suitable GPCR variant for crystallography.
Keywords: G-protein coupled receptor, Membrane protein, High expression, Screening, Receptor variants, Structural
study, Saccharomyces cerevisiaeBackground
G-proteincoupled receptors (GPCRs), which represent
the largest family of integral membrane proteins, play
pivotal roles in mediating signal transduction events in
response to ligands such as peptides and amines. GPCRs
are major therapeutic drug targets and represent ~ 30%
of the market share of all prescription drugs [1]. Al-
though the high-resolution 3D structures of the target
GPCRs provide good initial models for drug design, dif-
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reproduction in any medium, provided the orbottleneck for structural study. Large quantities of high-
quality pure protein are generally required for X-ray
crystallography. With the exception of rhodopsin [2-4],
which is naturally abundant and can be isolated from
rod outer membranes in the eyes, GPCRs generally are
not sufficiently abundant to be isolated from their en-
dogenous tissues. Therefore, overexpression in a heterol-
ogous host is needed. Various types of hosts have been
evaluated for use in GPCR expression, including bac-
teria, yeast, insect, and mammalian cells, as well as cell-
free systems [5, 6]. However, only a limited number of
GPCRs have been successfully expressed and purified on
a large scale. One reason for that may be their instability,
which is most likely due to their dynamic activity in the
membrane. Recent successes in structure determination
have demonstrated the importance of stabilizingl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cilitation of crystallization [7-13].
Because it is almost impossible to predict what
modifications will improve the expression and/or sta-
bility of receptors, suitable variants must be selected
from the pool of possible variants by trial and error.
To facilitate structural studies of GPCRs, a screening
system is required that will enable rapid selection of
variants. Insect cells have been used as a successful
host for structural study, but the screening is labori-
ous and time consuming. E. coli has recently been
used to screen the thermally stable GPCR variants of
turkey β1 adrenergic receptor (tADRB1) [14], human
adenosine A2a receptor (hADORA2A) [15, 16], and
rat neurotensin receptor 1 (rNTSR1) [17]. In addition
the crystal structures of the stabilized variants were
determined for tADRB1 and hADORA2A [18, 19].
However, only a limited number of functionally
expressed receptors have been successfully generated
in E. coli [20].
Yeast is a more preferred host for the expression
of GPCRs than E. coli. Yeast has a protein quality
control system similar to that of mammalian cells,
which enables numerous posttranslational modifica-
tions and correct disulfide formation of mammalian
membrane proteins. This similarity may lead to more
functional expression of GPCRs in yeast [21]. S. cere-
visiae in particular is stable for protein expression,
easy to manipulate, and quick to proliferate. S. cere-
visiae has been extensively tailored for the screening
of functional GPCR mutants [22]. In addition, many
GPCRs can be as highly expressed in yeast as in
mammalian cells [21, 23].
We previously established a GFP-based pipeline for the
expression and purification of non-GPCR membrane pro-
teins in S. cerevisiae [24, 25]. S. cerevisiae permits the
rapid cloning of genes of interest into the 2-μ plasmid by
homologous recombination, enabling the direct expres-
sion and evaluation of the proteins. The amount and in-
tegrity of the target membrane protein can be
estimated from the whole-cell fluorescence and in-gel
fluorescence after SDS-polyacrylamide gel electrophor-
esis (SDS-PAGE). Monodispersity, which is a good indica-
tor for purification, can be observed by fluorescence-
detection size exclusion chromatography (FSEC) [26].
The gene of a target protein can be transformed with
the divided PCR fragments in one step [27]. In the
present study, we demonstrate that the platform using
S. cerevisiae is very useful for the rapid construction
and evaluation of GPCR variants for structural study.
The stabilized GPCRs in S. cerevisiae were expressed
at higher levels in P. pastoris yeast. Finally, the stabi-
lized human histamine H1 receptor was successfully
purified for structural biology study.Results
GFP-based platform for the rapid construction and
evaluation of GPCR variants in S. cerevisiae
The GFP-based platform using S. cerevisiae for the con-
struction and evaluation of GPCR variants is illustrated
in Figure 1. The GPCR variants were designed and the
genes were generated as PCR fragments (Figure 1A).
The 2-μ plasmid named pDDGFP-2, which has a GAL1
promoter, and S. cerevisiae strain FGY217 were used
[24] (Figure 1B). This plasmid/strain combination
resulted in the best expression of membrane proteins.
The genes of interest were integrated into the plasmid
by homologous recombination in S. cerevisiae in one
step via introduction of a mixture of linearized plasmid
and PCR products. The clone harboring the GPCR vari-
ant is selected on an agar plate without uracil (Ura-).
After small-scale (10 mL) culturing, the functional
expressions are evaluated by radioligand-binding assays.
The monodispersity of the detergent-solubilized receptor
is assessed by FSEC by detecting the C-terminal GFP,
which enables the evaluation without purification. In the
present study, the SEC eluate was collected in a 96-well
microplate and the fluorescence was detected by a plate
reader following the existing protocol [24, 25]. There-
fore, a relatively large amount of samples (2 ~ 3 mg of
total membrane protein) was needed, and the mem-
branes were prepared from an intermediate-scale
(200 mL) culture. We have confirmed that a similar re-
sult could be obtained from a small-scale (10 mL) cul-
ture by using a fluorescence detector at the outlet of the
SEC column (data not shown). By omitting the
intermediate-scale culturing, this platform enables us to
perform a screening cycle within 6–7 days, compared to
16–18 days in P. pastoris or 30–35 days in insect cells
using baculovirus (Figure 1C).
Overexpression of full-length GPCRs in S. cerevisiae
First, 25 full-length GPCRs were expressed and evalu-
ated using this platform. The integrity of the GPCR-GFP
fusions examined by in-gel fluorescence after standard
SDS-PAGE [28] indicated that most of the GPCRs were
not degraded and appeared as a single major band in the
gel (Additional file 1: Figure S1). Table 1 shows the
expression levels of full-length receptors estimated by
the GFP fluorescence (total expression) and single-point
radioligand-binding assay (functional expression). With-
out any signal sequence and under standard culture con-
ditions (no additives and at 30 °C), the ligand-binding
activities of 12 GPCRs were zero or lower than 0.1 pmol/
mg. The N-terminal yeast alpha mating factor signal se-
quence which improved the ligand-binding activities of
GPCRs [29-32]. In the previous report on GPCR expres-
sion in P. pastoris, supplementation of dimethyl sulfoxide
(DMSO) and lowering induction temperature to 20 °C
Figure 1 Overview of the construction and evaluation platform of GPCR variants in S. cerevisiae. (A) Primer design of a variant. As an
example, the hHRH1 variant with truncation of the N-terminal region, a mutation at the 3.41 position in TM3 and T4L fusion to the i3-loop is
shown. The four PCR fragments are generated using the indicated primer pairs from full-length GPCR and T4L (Additional file 1: Table S1). The
same colored overlapping regions were necessary for homologous recombination in S. cerevisiae. (B) Illustration of a cycle from construction
design to evaluation for the GPCR variants. (C) Flow and time-scale of the construction and evaluation of GPCR variants in three hosts. Schemes
for small-scale culturing are shown in yellow and orange, respectively. Evaluations by ligand-binding assays and FSEC are shown in cyan and
green, respectively. Vec.: preparation of expression vector, Bac.: preparation of Bacmid, Ura-: selection on a Ura- plate, MD: selection on a
minimum dextrose (MD) plate, Gen: selection on a geneticine plate, P1 and P2: P1 and P2 virus preparation, respectively.
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Then four culture conditions were examined: the presence
or absence of 2.5% DMSO and two induction temperatures
(20 °C, 30 °C). The functional expression of 24 of 25
GPCRs was increased in S. cerevisiae in the optimized con-
ditions. For many receptors, there was little correlation be-
tween the intensity of GFP fluorescence and ligand-binding
activity, suggesting that the intensity of GFP fluorescence it-
self is not a good indicator of functional expression in thisplatform. After these optimizations, 25 GPCRs were func-
tionally expressed. However, the expression level remained
insufficient for structural study.
Use of S. cerevisiae as a platform for the construction and
evaluation of GPCR variants
We generated and evaluated the variants of the three
GPCRs shown in Table 2 (hCHRM2, hHRH1, hNTSR1)
using the GFP-based platform in S. cerevisiae. In addition,
Table 1 Summary of the expression level and functional activity of the 25 GPCRs expressed in S. cerevisiae under
different culture conditions in small-scale cultures
α-factor (−) α-factor (+)
Temp 30 °C 20 °C 30 °C 20 °C
DMSO − + − + − + − +
Acetylcholine receptor hCHRM2 TE (mg/L) 1.5 1.5 1.7 1.6 0.53 0.78 0.62 0.56
FE (pmol/mg) 0.03 0.12 0.05 0.21 0.08 0.28 0.30 0.66
Adenosine receptor hADORA2A TE (mg/L) 0.20 0.17 0.06 0.06 0.70 0.68 0.84 0.92
FE (pmol/mg) 5.3 6.8 2.4 2.4 24 25 16 20
Adrenergic receptor hADRB2 TE (mg/L) 1.5 1.6 0.76 0.93 0.81 1.0 0.91 0.71
FE (pmol/mg) 0.06 0.07 0.10 0.18 0.36 0.40 0.52 1.1
Dopamine receptor hDRD1 TE (mg/L) 0.53 0.81 0.75 0.9 0.44 0.62 0.54 0.57
FE (pmol/mg) 0.07 0.02 0.05 0.01 0.01 0.03 0.01 0.04
hDRD2 TE (mg/L) 0.21 0.12 0.26 0.24 0.21 0.32 0.34 0.31
FE (pmol/mg) 0.37 0.58 0.72 1.57 0.35 1.09 1.6 3.2
hDRD4 TE (mg/L) 2.0 2.5 1.1 1.3 0.78 0.79 0.8 1.3
FE (pmol/mg) 0.21 0.25 0.19 0.3 0.22 0.34 0.17 0.17
Histamine receptor hHRH1 TE (mg/L) 0.95 1.1 1.6 1.7 0.37 0.53 0.65 0.63
FE (pmol/mg) 0 0 0.34 0.61 0 0.15 0 0
hHRH3 TE (mg/L) 0.96 1.0 0.61 0.55 0.48 0.64 0.61 0.81
FE (pmol/mg) 0.4 0.62 0.24 0.11 0.74 0.87 0.27 0.32
hHRH4 TE (mg/L) 0.38 0.51 0.67 0.75 0.33 0.55 0.42 0.52
FE (pmol/mg) 0.45 0.6 0.16 0.27 0.68 1.1 0.22 0.15
Neuropeptide Y hNPY1R TE (mg/L) 0.11 0.11 0.11 0.11 0.36 0.4 0.25 0.26
FE (pmol/mg) 0 0 0 0 0 0.12 0.07 0.21
hNPYR2 TE (mg/L) 0.51 0.54 0.24 0.23 0.18 0.22 0.2 0.19
FE (pmol/mg) 0 0.14 0.05 0 0 0 0.03 0
hNPYR4 TE (mg/L) 1.0 1.5 0.91 1.2 0.27 0.61 0.24 0.27
FE (pmol/mg) 0.13 0.18 0.1 0.07 0.21 0.35 0 0
hNPYR5 TE (mg/L) 0.31 0.46 0.82 0.89 0.34 0.51 0.52 0.61
FE (pmol/mg) 0.04 0.02 0.07 0.13 0 0.01 0 0
Neurotensin receptor hNTSR1 TE (mg/L) 0.59 1.0 0.87 0.93 0.52 0.8 0.83 1.1
FE (pmol/mg) 0.15 0.15 0.15 0.15 0.32 0.43 0.3 0.78
hNTSR2 TE (mg/L) 0.73 1.3 1.4 1.5 0.65 1.0 0.8 0.89
FE (pmol/mg) 0.18 0.21 0.26 0.18 0.19 0.19 0.11 0.16
Opioid receptor hOPRK1 TE (mg/L) 0.54 0.76 0.4 0.34 0.24 0.32 0.27 0.29
FE (pmol/mg) 0 0.08 0.09 0.16 0 0.11 0.1 0.15
Prostanoid receptor hPTGER2 TE (mg/L) 0.24 0.16 0.2 0.18 0.28 0.43 0.49 0.48
FE (pmol/mg) 0 0 0.19 0 0 0.18 0.1 0.47
hPTGER4 TE (mg/L) 0.11 0.15 0.09 0.11 1.4 1.7 1.5 1.4
FE (pmol/mg) 0 0 0 0 0 0 0.4 0
hTBXA2R TE (mg/L) 0.52 0.63 0.26 0.26 0.21 0.21 0.34 0.32
FE (pmol/mg) 0.15 0.23 0.05 0.02 0.03 0 0.78 0.7
Serotonin receptor hHTR1B TE (mg/L) 0.9 1.1 0.46 0.58 0.34 0.23 0.46 0.46
FE (pmol/mg) 0.54 0.62 0.71 0.48 0.89 1.1 2.0 1.9
hHTR1D TE (mg/L) 0.34 0.53 0.67 0.76 0.29 0.3 0.33 0.22
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Table 1 Summary of the expression level and functional activity of the 25 GPCRs expressed in S. cerevisiae under
different culture conditions in small-scale cultures (Continued)
FE (pmol/mg) 0.06 0.03 0.33 0.46 0.46 0.52 1.7 1.6
hHTR5A TE (mg/L) 0.3 0.62 0.48 0.59 0.2 0.25 0.23 0.23
FE (pmol/mg) 0.02 0.18 0 0.07 0.24 0.34 0 0
Tachykinin receptor hTACR1 TE (mg/L) 1.1 1.7 1.1 1.1 0.67 0.83 0.65 0.57
FE (pmol/mg) 0 0.45 0.14 0.02 0.60 0.59 0.09 0.15
hTACR2 TE (mg/L) 1.4 1.7 2.5 2.2 0.46 0.71 0.96 0.86
FE (pmol/mg) 0.40 0.85 1.1 2.9 0.75 0.65 1.3 3.8
rTACR2 TE (mg/L) 0.11 0.10 0.06 0.04 0.56 0.86 1.0 1.1
FE (pmol/mg) 0.25 0.2 0.08 0.06 1.3 1.9 5.2 7.4
“TE” represents the total expression level estimated from whole-cell GFP fluorescence (mg/L culture). The intensity of 200 μL of 1 μM purified yEGFP in the 96-well
plate was 7500 [rfu]. Whole-cell fluorescence was measured in a 200-μL cell suspension by using cultures at the same cell density as the culture. Therefore, the
expression level was calculated from: TE [mg/L] = (GFP counts of whole cell [rfu])/(7500*106 [rfu*L/mol])* (molecular weight*103 [mg/mol]). “FE” represents the
functional activity from a single-point radioligand binding assay (pmol/mg membrane protein). Conditions highlighted in bold type are the best and second-best
conditions for the GFP-based expression level and the functional activity.
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has been solved as a T4L-fusion [34], was also generated.
To construct GPCR variants, the following four variant
modules were considered: (1) A truncation of flexible long
N- (Nd) or C-terminal residues (Cd), which effectively
increases GPCR expression in some reported cases (e.g.,
ref. [35]). (2) A point mutation at the 3.41 position in trans-
membrane helix 3 (Additional file 1: Figure S2A). TheTable 2 GPCR variants constructed and evaluated in S.
cerevisiae in this study
GPCR Variant name Deletions and mutations
hADRB2 FL full-length ADRB2 (1–413)
ADRB2mut ADRB2(1–365), E122W, N187E
hCHRM2 FL full-length CHRM2 (1–466)
Nd-i3d CHRM2 (11–466), i3d(233–380)
Nd-M112W-i3d CHRM2 (11–466), M112W, i3d(233–380)
hHRH1 FL full-length HRH1 (1–487)
Nd-i3d HRH1 (20–487), i3d (229–397)
Nd-T4L HRH1 (20–487), T4L
Nd-F116W-i3d HRH1 (20–487), F116W, i3d (229–397)
Nd-F116W-T4L HRH1 (20–487), F116W, T4L
hNTSR1 FL full-length NTSR1 (1–418)
Nd-Cd NTSR1 (43–385)
Nd-T4L-Cd NTSR1 (43–385), T4L
Nd-L157W-Cd NTSR1 (43–385), L157W
Nd-L157W-T4L-Cd NTSR1 (43–385), L157W, T4L
NTSR1 (43–385) means that the N- and C-terminal residues are truncated, the
receptor starts from residue 43, and the receptor ends with residue 385.
E122W, M112W, F116W and L157W are the mutations to tryptophan at
position 3.41. Deletion of the i3-loop from position 229 to 297 is indicated as
i3d (229–297). T4L indicates the fusion of the T4 lysozyme sequence between
TM5 and TM6.numbering is based on the general indexed position in the
Ballesteros-Weinstein system [36]. Mutations at this pos-
ition reportedly increase the thermal stability of hADRB2
[37]. (3) A deletion mutant of a long third intracellular loop
(i3-loop) (abbreviated as i3d; Additional file 1: Figure S2B).
A long i3-loop potentially becomes a target of degradation
or receptor destabilization on the host cell surface. For
muscarinic receptors, deletion of the i3-loop results in
higher functional expression [38, 39]. (4) Replacement of
part of the i3-loop by T4 lysozyme (T4L, residues from 2 to
161) (Additional file 1: Figure S2B); this replacement has
been successful in crystallization and structural determin-
ation of hADRB2, hADORA2A, hDRD3 and hCXCR4 in
cubic phase crystals [8, 11-13].
After small-scale culturing, the total receptor expres-
sions and functional expressions were determined by
GFP fluorescence and radioligand-binding assay, respect-
ively (Additional file 1: Figure S3). These results showed
that the intensity of GFP fluorescence itself is not a good
indicator of functional expression. The ligand binding
activity and monodispersity of the detergent-solubilized
receptor of the variants that portrayed improved func-
tional expression are shown in Figure 2. The hADRB2
variant Cd-E122W-N187E showed a~ 10-fold increase
in ligand-binding activity. The hCHRM2 variant Nd-i3d
showed a 2.5-fold increase. The hHRH1 variants Nd-i3d
and Nd-T4L displayed 7- and 26-fold increased activity,
respectively. In hNTSR1, mutagenesis at the 3.41-position
(Nd-L157W-Cd and Nd-L157W-T4L-Cd) increased activ-
ity by~ 1.5-fold. Importantly, the variants that showed
improved activity also exhibited improved FSEC profiles
after solubilization with the mixed micelle of n-Dodecyl-
β-D-maltopyranoside (DDM) and cholesteryl hemisucci-
nate (CHS), which is commonly used for purification of
GPCRs. This indicates that there is a correlation between
Figure 2 Specific binding activity (left) and FSEC profile (right) of the full-length and improved variants expressed in S. cerevisiae.
(A) hADRB2, (B) hCHRM2, (C) hHRH1, and (D) hNTSR1. FSEC was performed with the Superose 6 10/300 column. The colors of the FSEC
chromatogram correspond to those of the binding activity. The void peak is denoted by an asterisk. An arrow indicates the target peak of
GPCR-GFP fusion.
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monodispersity in GPCR variants.
Expression of the GPCR variants in other hosts
Human HRH1-Nd-T4L variant showed a high expres-
sion (16 pmol/mg) and good FSEC profile in S. cerevi-
siae. However, the expression of the other GPCR
variants remained too low for purification. If the
improved variants could be expressed in another host at
higher levels, purification would be facilitated. While in-
sect cells are currently known as the most successful
host for GPCR expression for structural study, our re-
cent successes in the structural determination of hHRH1
and human adenosine A2a receptor (hADORA2a) were
achieved by using P. pastoris as a host cell [40, 41]. P.
pastoris is easier to handle compared to insect cells, and
can generate milligram quantities of high-quality mam-
malian GPCR protein as well as insect cells [42-46].
Therefore, we attempted to express selected GPCR var-
iants in P. pastoris.
Improvements of ligand-binding activity and FSEC
profiles of GPCR variants were also observed in P. pas-
toris (Figure 3). The hADRB2 variant E122W-N187E-Cdexhibited a large improvement in ligand-binding activity
(80-fold) and a larger peak derived from monodisperse
receptor in P. pastoris. In the hCHRM2 variant Nd-i3d,
improvements in both ligand-binding activity (2-fold)
and monodispersity were observed. For hHRH1, sub-
stantial improvements in ligand-binding activity and
monodispersity in FSEC were observed for both Nd-i3d
and Nd-T4L (by 6- and 4-fold, respectively). Although
the improvements in ligand-binding activity of the
hNTSR1 variants Nd-157W-Cd and Nd-157W-T4L-Cd
were only ~ 1.5-fold in S. cerevisiae, ligand-binding activ-
ity and monodispersity were largely improved in P. pas-
toris. We confirmed that improvements of GPCR
variants were also observed in Sf9 insect cells (Add-
itional file 1: Figure S4). For the receptors in the present
study, the expression level in P. pastoris was the same or
higher than that in insect cells.
Purification of the GPCR variants
The variants, hHRH1-Nd-i3d expressed in P. pastoris and
hHRH1-Nd-T4L expressed in S. cerevisiae, were success-
fully purified in milligram quantities from a large-scale cul-
ture. The yield of functional expression estimated from
Figure 3 Evaluation of the GPCR variants expressed in P.
pastoris. The specific binding activities (left) and FSEC profiles (right)
of full-length GPCRs and the improved GPCR variants expressed in P.
pastoris are shown. The colors of the chromatogram correspond to
those in the binding assays. (A) hADRB2, (B) hCHRM2, (C) hHRH1, (D)
hNTSR1. FSEC was performed with a Superose 6 10/300 column. The
void peak is denoted by an asterisk. The arrow indicates the target
peak of GPCR fused to GFP.
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for hHRH1-Nd-i3d expressed in P. pastoris and more than
0.04 mg for hHRH1-Nd-T4L expressed in S. cerevisiae. The
yield estimated from whole-cell GFP fluorescence inten-
sities were ~5 mg for hHRH1-Nd-i3d expressed in P. pas-
toris and ~1.2 mg for hHRH1-Nd-T4L expressed in S.
cerevisiae. The final yield after purification of hHRH1-Nd-
i3d expressed in P. pastoris, hHRH1-Nd-T4L expressed in
S. cerevisiae were 0.3~0.4 mg and 0.04 mg per 1 L culture,
respectively. These purified GPCR variants showed
90~95% purity judging from SDS-PAGE and showed a
high degree of monodispersity judging from size exclusion
chromatography (SEC) with absorbance detection at
280 nm (Figure 4). The SEC profile of purified hHRH1-Nd-
T4L expressed in P. pastoris was also monodisperse as
described in our recent report [47].
Discussion
Approximately 800 GPCRs have been identified in the
human genome. More than 40 receptors are now tar-
geted by drugs, and more than 300 receptors could po-
tentially be future drug targets [48, 49]. For a better
understanding of ligand recognition and drug design,
three-dimensional structures will be needed for each re-
ceptor. However, at present, only a handful of GPCR
structures have been determined. One major bottleneck
that hampers structural study is clearly the expression
and purification of functional receptors. As shown in
this study and many previous reports on GPCR expres-
sion, the expression level and/or stability of wild-type
receptors are not sufficient. Therefore, for successful
structural study, it is necessary to stabilize the receptors
for high-level expression and crystallization. We demon-
strated that a platform using S. cerevisiae enabled the
rapid construction and selection of stabilized GPCR
variants.
In this study, we presented examples of receptors that
improved ligand-binding activity and monodispersity
through the introduction of variant modules. If the ini-
tial variant module does not work well, optimizations
might be needed to achieve a higher expression, such as
changes in the length of the N- or C-terminal truncation
and positions of the i3-loop deletion and/or the insertion
of T4 lysozyme. Thermal stabilization will be required
for the intrinsically unstable receptors, or for receptors
that need to be crystallized in a smaller detergent. Ther-
mal stabilizations have been achieved by mutagenesis to
tryptophan at position 3.41 in TM3, alanine scanning
mutagenesis, or random mutagenesis [14, 15, 17, 37, 50].
This platform using S. cerevisiae should facilitate such
extensive construction screening much more easily and
rapidly than in insect cells or mammalian cells. Our
results suggest that there is a correlation between the
ligand-binding activity and monodispersity; that is, a
Figure 4 Purification of the receptor variant. (A) hHRH1-Nd-i3d expressed in P. pastoris, and (B) hHRH1-Nd-T4L expressed in S. cerevisiae. The
size-exclusion chromatogram using Superdex 200 10/300 is shown in the left panel, and the Coomassie blue-stained SDS-PAGE gel is shown in
the right panel. Lane 1, molecular weight marker. Lane 2, purified receptor variant. Arrows indicate the purified receptors.
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sion. Therefore, this platform for engineering stabilized
variants could also be applicable to orphan GPCRs, for
which functional assays such as ligand-binding assay
would be difficult.
Higher expression of the variants than that of the full-
length receptors achieved in S. cerevisiae was also
observed in P. pastoris for hADRB2, hCHRM2, hHRH1
and hNTSR1. We confirmed that improvements of GPCR
variants were also observed in insect cells. The best host
to yield a high quality and quantity of GPCR may depend
on the GPCR type. It has been reported that the thermally
stabilized NTSR1 variants selected in E. coli were also
expressed at higher levels in P. pastoris and mammalian
cells [17]. Therefore, the combination of E. coli or S. cere-
visiae for rapid screening and P. pastoris for a large scale
of expression could be a dominant strategy for the struc-
tural study of GPCR and other membrane proteins.
The purified hHRH1 variants expressed in S. cerevisiae
and P. pastoris showed a high degree of monodispersity
analyzed by SEC. The recent structural determinations of
hHRH1 and hADORA2a were achieved by using P. pas-
toris expression system [40, 41]. These facts strongly sug-
gest the potential of yeast as an expression host, which
provide high quality receptor protein enough for crystal-
lography. Nuclear magnetic resonance (NMR) spectros-
copy is a promising tool to know the ligand binding to
extracellular surface of GPCRs, which is unclear in crystal
structure in many cases [51]. Yeast has been used for pro-
ducing a large amount of isotope-labeled recombinant
protein. Our platform can also be a useful system for
NMR analysis.
Conclusions
We demonstrated that the GFP-based S. cerevisiae system
served as an easy-to-handle and rapid platform for the
construction and evaluation of GPCR variants. This plat-
form should be a cost-effective and powerful tool for the
extensive screening to identify a highly expressed andstable variant for crystallography. Higher expression of
variant achieved in S. cerevisiae should be also achieved in
other hosts. The combination of S. cerevisiae for rapid
screening and P. pastoris for high expression could be an
effective strategy for the structural study of GPCR.
Methods
S. cerevisiae transformation and small-scale
overexpression
The transformation and overexpression in S. cerevisiae
were basically performed according to the previous
method [25]. We here used the 2-μ vector pDDGFP-2
[24] and the vacuolar protease-deficient S. cerevisiae
FGY217 (MATα, ura3-52, lys2Δ201, and pep4Δ) [52].
DNA fragments encoding the target GPCRs were ampli-
fied with the KOD Plus DNA polymerase (TOYOBO,
Tokyo, Japan), with forward and reverse primers con-
taining a 20–30 bp gene-specific region and a 30 bp
homologous region [25]. Approximately 30 ng of
pDDGFP-2 and 3 μL of 1 ~ 4 PCR fragments of a GPCR
(which have a ~30 bp overlapping region with each
other) were transformed. Transformants were selected
on Ura- plates at 30 °C.
Colonies of transformants harboring the target GPCR
were grown in 5 mL of Ura- medium with 2% glucose in
50 mL aerated capped tubes (TPP, Switzerland) at 30 °C
overnight. The cultures were diluted to an OD600 of 0.12
and cultured in 10 mL of Ura- medium with 0.1% glu-
cose at 30 °C. At an OD600 of 0.6, galactose was added
to the culture to a final concentration of 2%, DMSO was
added as needed, and the temperature was lowered to
20 °C as needed. After shaking for 20–22 h at 30 °C (or
40 h at 20 °C), the cells were harvested, and the cell pel-
lets were resuspended in 700 μL of buffer A (50 mM
Tris–HCl, pH 7.5, 5 mM EDTA, 10% glycerol, 0.12 M
sorbitol, and complete protease inhibitor cocktail
[Roche]). The cell suspensions were diluted 20-fold in
buffer A, and whole-cell GFP fluorescence was measured
with a SpectraMax M2e microplate reader (Molecular
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an emission wavelength of 525 nm was measured by
using a 515 nm cutoff filter after excitation at 490 nm.
Purified yEGFP was used as a standard for estimating
overexpression.
Membranes from small-scale (10 mL) cultures were pre-
pared as follows. A yeast cell suspension (700 μL) was
transferred to 2 mL tubes containing 500 μL of acid-
washed, dry, 425 to 600 μm glass beads (Sigma). Cells
were disrupted on a Cutemixer CM-1000 (EYELA, Tokyo,
Japan) at 2,500 rpm for 40 min at 4 °C. The samples were
examined microscopically to confirm that >90% of the
cells were broken. Unbroken cells and debris were pelleted
by centrifugation, and the supernatant was transferred
into an ultra-centrifuge tube. Yeast membranes were col-
lected by ultracentrifugation at 100,000 g for 30 min at 4 °
C. Prepared membranes were snap-frozen in liquid nitro-
gen and stored at −80 °C, or stored on ice and used within
24 h.
Intermediate and large-scale overexpression and
membrane preparation in S. cerevisiae
Yeast clones harboring the target receptor were inoculated
in Ura- medium with 2% glucose and grown at 30 °C over-
night. The yeast culture was diluted to an OD600 of 0.12 in
a total volume of 200 mL or more than 1 L of Ura- medium
with 0.1% glucose in a 500 mL baffle flask or 2.5 L Tunair
flask (Sigma-Aldrich, USA), respectively. The culture was
shaken at 250 rpm at 30 °C, and expression was induced by
adding galactose to a final concentration of 2% when the
culture reached an OD600 of 0.6. After induction, the flasks
were shaken for 20 h (30 °C cultures) or 40 h (20 °C cul-
tures), and the cells were harvested. Cells were washed
once with lysis buffer (50 mM Tris–HCl, pH 7.5, 100 mM
NaCl, 5% glycerol, complete protease inhibitor cocktail, and
2 mM EDTA), snap-frozen in liquid nitrogen, and stored at
−80 °C.
The intermediate-scale cells were resuspended in the
lysis buffer and disrupted in a 50 mL tube using an equal
volume of glass beads on a Cutemixer at 2,500 rpm for
40 min at 4 °C. The large-scale cells were disrupted in a
2 L baffled flask using an equal volume of glass beads on
an Innova 44R shaker (New Brunswick Scientific Inc.,
USA) for 60 min at 4 °C. Unbroken cells and debris were
removed by centrifugation, the supernatant was trans-
ferred to ultracentrifuge tubes, and the membranes were
pelleted by centrifugation at 100,000 g for 60 min at 4 °
C. The pellet was suspended in buffer containing
50 mM Tris–HCl, pH 8.0, 120 mM NaCl, 20% glycerol
and protease inhibitor cocktail, and stored at −80 °C.
Radioligand-binding assays
Membranes containing each GPCR-GFP were uni-
formly resuspended by sonication in individual assaybuffers (Additional file 1: Table S2). Membrane pro-
teins were quantified with the bicinchoninic acid
(BCA) assay method (Pierce, USA). Membrane sus-
pensions (5–20 μg) were incubated in triplicate with
specific radioactively-labeled ligands (Additional file 1:
Table S2) for 1 h at 25 °C. Nonspecific binding was
determined in the presence of excess unlabeled lig-
and. Membranes were trapped on Whatman GF/B filters
that were presoaked in 0.3% polyethylenimine. The bound
and free radioligands were separated by washing three
times with water. The retained radioactivity was measured
on an LCS-5100 liquid scintillation counter (ALOKA).
Fluorescence size exclusion chromatography (FSEC)
Membrane suspensions of GPCRs were solubilized in buf-
fer containing 50 mM Tris–HCl, pH 7.5, 200 mM NaCl,
protease inhibitor, and 1% detergent at a final concentration
of 3 mg/mL total protein at 4 °C for 1 h with mild agitation.
Insoluble material was pelleted by ultracentrifugation at
100,000 g at 4 °C for 30 min. FSEC was performed with a
Superose 6 10/300 column (GE Healthcare) on a Biologic
Chromatography System (BioRad) with 500 μL of solubi-
lized sample. The column was preequilibrated with running
buffer (20 mM Tris–HCl, pH 7.5, 150 mM NaCl, 0.05%
DDM/0.01% CHS). Fractions (0.2 mL) were collected in a
96-well microplate from the first 6 mL eluted after sample
injection. Fluorescence emission at 525 nm was measured
using a SpectraMax M2e plate reader with a 515 nm cutoff
filter after excitation at 490 nm.
Overexpression in P. pastoris
Using the GPCR-integrated pDDGFP-2 plasmids as tem-
plates, coding regions of the GPCR-GFP fusion proteins
were PCR-amplified with a forward primer containing a
BamHI site (5′-CTA GAA CTA GTG GAT CCA CCA
TG-3′) and a reverse primer containing an EcoRI site (5′-
GCT TGA TAT CGA ATT CCT GCA GTT AAT G-3′).
The PCR products were digested with BamHI and EcoRI
and subcloned into the pPIC9K vector. The vector was line-
arized using PmeI. Transformation, clone selection, and
small-scale culturing were performed as previously
described [53]. The selected transformants were stored in
glycerol stocks at −80 °C. Intermediate-scale (200 mL) and
large-scale (more than 1 L) culturing were performed under
the same conditions as small-scale culturing, with a
500 mL baffled flask and 2.5 LTuniar Flask (Sigma-Aldrich,
USA). P. pastoris cells from small- and intermediate-scale
cultures were disrupted with glass beads and membranes
were prepared in the same way as for S. cerevisiae.
Purification of GPCR variants
Purification of hHRH1-Nd-i3d expressed in P. pastoris and
hHRH1-Nd-T4L expressed in S. cerevisiae was performed
according to our previous report [41]. In brief, the
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(w/v) DDM/0.2% (w/v) CHS, and the unsolubilized mater-
ial was separated by ultracentrifugation. The GPCR-GFP
fusion protein was purified with TALON IMAC resin
(Clontech). The purified protein was concentrated, and
then the protein was treated overnight with His-tagged
TEV protease (expressed and purified in house). TEV pro-
tease and the cleaved His-tagged GFP were removed from
the sample by passing the sample through TALON resin
and collecting the flow through. All the purification steps
were performed in the presence of 100 μM pyrilamine.
Additional file
Additional file 1: Supplementary information. Table S1 Primers used
for the construction of hHRH1 variant (Nd-F116W-T4L). Table S2 Ligands
and conditions for the single point radioligand binding assays. Figure S1
In-gel fluorescence of 25 GPCR-GFP fusions expressed in S. cerevisiae.
Arrowheads represent the GPCR-GFP fusion bands and the asterisk
represents an endogenous fluorescent ‘background’ protein from S.
cerevisiae that migrates at approximately 70 kDa. Figure S2 Construction
design of GPCR variants. (A) Sequence alignments of transmembrane 3
(TM3) of the GPCRs in this study with bovine rhodopsin and human
ADORA2A. The number above the sequence is the general indexed
position based on the Ballesteros–Weinstein system. The 3.41 position for
receptor stabilization is highlighted in yellow. (B) Sequence alignments of
TM5, i3-loop, and TM6. The position where the T4 lysozyme sequence is
fused is shown in red. To truncate the long i3 loop, the residues shown
in blue were connected for each receptor. Figure S3 Fluorescence
intensity and activity of GPCR variants screened in S. cerevisiae. Whole-cell
GFP fluorescence (arbitrary unit, bar graph) and specific activity of the
membrane by radioligand binding assays (black square plot) of full-
length GPCRs and GPCR variants constructed in S. cerevisiae. (A) hADRB2,
(B) hCHRM2, (C) hHRH1, and (D) hNTSR1. Figure S4 Evaluation of the
GPCR variants expressed in Sf9 insect cells. The specific binding activities
(left) and FSEC profiles (right) of full-length GPCRs and the improved
GPCR variants expressed in Sf9 cells are shown. The colors of the
chromatogram correspond to those in the binding assays. (A) hADRB2,
(B) hCHRM2, (C) hHRH1, (D) hNTSR1. FSEC was performed with a
Superose 6 10/300 column. The void peak is denoted by an asterisk. The
arrow indicates the target peak of GPCR fused to GFP.
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